FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792813960> ?p ?o ?g. }

• W2792813960 abstract "CD44v6 is overexpressed in a variety of cancers, rendering it a promising target for radio-immunotherapy (RIT). In this study, we have characterized a novel engineered recombinant monoclonal anti-CD44v6 antibody, AbN44v6, and assessed its potential for use in RIT using either 177Lu or 131I as therapeutic radionuclides. In vitro affinity and specificity assays characterized the binding of the antibody labeled with 177Lu, 125I or 131I. The therapeutic effects of 177Lu-AbN44v6 and 131I-AbN44v6 were investigated using two in vitro 3D tumor models with different CD44v6 expression. Finally, the normal tissue biodistribution and dosimetry for 177Lu-AbN44v6 and 125I-AbN44v6/131I-AbN44v6 were assessed in vivo using a mouse model. All AbN44v6 radioconjugates demonstrated CD44v6-specific binding in vitro. In the in vitro 3D tumor models, dose-dependent therapeutic effects were observed with both 177Lu-AbN44v6 and 131I-AbN44v6, with a greater significant therapeutic effect observed on the cells with a higher CD44v6 expression. Biodistribution experiments demonstrated a greater uptake of 177Lu-AbN44v6 in the liver, spleen and bone, compared to 125I-AbN44v6, whereas 125I-AbN44v6 demonstrated a longer circulation time. In dosimetric calculations, the critical organs for 177Lu-AbN44v6 were the liver and spleen, whereas the kidneys and red marrow were considered the critical organs for 131I-AbN44v6. The effective dose was in the order of 0.1 mSv/MBq for both labels. In conclusion, AbN44v6 bound specifically and with high affinity to CD44v6. Furthermore, in vitro RIT demonstrated growth inhibition in a CD44v6-specific activity-dependent manner for both radioconjugates, demonstrating that both 177Lu-AbN44v6 and 131I-AbN44v6 may be promising RIT candidates. Furthermore, biodistribution and dosimetric analysis supported the applicability of both conjugates for RIT. The CD44v6-specific therapeutic effects observed with radiolabeled AbN44v6 in the 3D tumor models in vitro, combined with the beneficial dosimetry in vivo, render AbN44v6 a potential candidate for RIT." @default.
• W2792813960 created "2018-03-29" @default.
• W2792813960 creator A5002426578 @default.
• W2792813960 creator A5024855606 @default.
• W2792813960 creator A5060280323 @default.
• W2792813960 creator A5067267559 @default.
• W2792813960 creator A5084039192 @default.
• W2792813960 date "2018-04-11" @default.
• W2792813960 modified "2023-10-16" @default.
• W2792813960 title "Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy" @default.
• W2792813960 cites W1667479538 @default.
• W2792813960 cites W1672605931 @default.
• W2792813960 cites W1863821115 @default.
• W2792813960 cites W1958434205 @default.
• W2792813960 cites W1977559211 @default.
• W2792813960 cites W1977710662 @default.
• W2792813960 cites W1979206002 @default.
• W2792813960 cites W1983567075 @default.
• W2792813960 cites W2002518487 @default.
• W2792813960 cites W2013956896 @default.
• W2792813960 cites W2029039082 @default.
• W2792813960 cites W2031602267 @default.
• W2792813960 cites W2041706011 @default.
• W2792813960 cites W2047498280 @default.
• W2792813960 cites W2062655552 @default.
• W2792813960 cites W2103795331 @default.
• W2792813960 cites W2113584131 @default.
• W2792813960 cites W2125816970 @default.
• W2792813960 cites W2129075907 @default.
• W2792813960 cites W2130423119 @default.
• W2792813960 cites W2136138562 @default.
• W2792813960 cites W2137619896 @default.
• W2792813960 cites W2139619397 @default.
• W2792813960 cites W2149268421 @default.
• W2792813960 cites W2156480768 @default.
• W2792813960 cites W2172991569 @default.
• W2792813960 cites W2185254822 @default.
• W2792813960 cites W2192921573 @default.
• W2792813960 cites W2204379188 @default.
• W2792813960 cites W2213346842 @default.
• W2792813960 cites W2224158681 @default.
• W2792813960 cites W2294365458 @default.
• W2792813960 cites W2330998901 @default.
• W2792813960 cites W2346293763 @default.
• W2792813960 cites W2370071580 @default.
• W2792813960 cites W2396257069 @default.
• W2792813960 cites W2408693074 @default.
• W2792813960 cites W2411125742 @default.
• W2792813960 cites W2428018828 @default.
• W2792813960 cites W2431682936 @default.
• W2792813960 cites W2490672095 @default.
• W2792813960 cites W2511468067 @default.
• W2792813960 cites W2637844851 @default.
• W2792813960 cites W2773258427 @default.
• W2792813960 cites W4249826880 @default.
• W2792813960 cites W81435281 @default.
• W2792813960 cites W144437338 @default.
• W2792813960 doi "https://doi.org/10.3892/ijo.2018.4364" @default.
• W2792813960 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5919712" @default.
• W2792813960 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29658563" @default.
• W2792813960 hasPublicationYear "2018" @default.
• W2792813960 type Work @default.
• W2792813960 sameAs 2792813960 @default.
• W2792813960 citedByCount "3" @default.
• W2792813960 countsByYear W27928139602020 @default.
• W2792813960 countsByYear W27928139602021 @default.
• W2792813960 crossrefType "journal-article" @default.
• W2792813960 hasAuthorship W2792813960A5002426578 @default.
• W2792813960 hasAuthorship W2792813960A5024855606 @default.
• W2792813960 hasAuthorship W2792813960A5060280323 @default.
• W2792813960 hasAuthorship W2792813960A5067267559 @default.
• W2792813960 hasAuthorship W2792813960A5084039192 @default.
• W2792813960 hasBestOaLocation W27928139601 @default.
• W2792813960 hasConcept C104317684 @default.
• W2792813960 hasConcept C150903083 @default.
• W2792813960 hasConcept C153911025 @default.
• W2792813960 hasConcept C159654299 @default.
• W2792813960 hasConcept C202751555 @default.
• W2792813960 hasConcept C203014093 @default.
• W2792813960 hasConcept C207001950 @default.
• W2792813960 hasConcept C2776146153 @default.
• W2792813960 hasConcept C2777092746 @default.
• W2792813960 hasConcept C2777701055 @default.
• W2792813960 hasConcept C2777807558 @default.
• W2792813960 hasConcept C2780007613 @default.
• W2792813960 hasConcept C2780931953 @default.
• W2792813960 hasConcept C40767141 @default.
• W2792813960 hasConcept C502942594 @default.
• W2792813960 hasConcept C542903549 @default.
• W2792813960 hasConcept C55493867 @default.
• W2792813960 hasConcept C86803240 @default.
• W2792813960 hasConcept C8891405 @default.
• W2792813960 hasConcept C98274493 @default.
• W2792813960 hasConceptScore W2792813960C104317684 @default.
• W2792813960 hasConceptScore W2792813960C150903083 @default.
• W2792813960 hasConceptScore W2792813960C153911025 @default.
• W2792813960 hasConceptScore W2792813960C159654299 @default.
• W2792813960 hasConceptScore W2792813960C202751555 @default.
• W2792813960 hasConceptScore W2792813960C203014093 @default.
• W2792813960 hasConceptScore W2792813960C207001950 @default.

• next